As such, treatment of non-diabetic (ND) subjects with rosiglitazone (RSG) has been shown to increase circulating visfatin levels [12], whilst, contrastingly, pioglitazone treatment has led to no apparent change in circulating levels in either T2DM or ND subjects [13], [14]. This evidence concerns the gene NAMPT and type 2 diabetes mellitus.